Amgen executives and local members of the community recently gathered at the company’s global headquarters in Thousand Oaks, Calif., to celebrate the groundbreaking of a new state-of-the-art center for science and innovation. The $600 million investment, announced in September 2025, will bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of life-changing therapeutics for patients with serious diseases.
“Today’s groundbreaking is a marker of what comes next in our mission to serve patients,” said Amgen CEO Bob Bradway at the event. “With the first shovel in the ground we’re reaffirming something essential: We discover here, we manufacture here, we deliver for patients from Thousand Oaks to all around the world.”
Since 2017, Amgen has invested more than $40 billion in U.S. manufacturing and R&D, including nearly $5 billion in domestic capital projects. In addition to this expansion in California, Amgen has recently announced investments in North Carolina, Ohio, and Puerto Rico. The enactment of pro-growth tax policies has further facilitated Amgen’s ability to invest domestically in cutting-edge science and manufacturing.
Continued Innovation, More Jobs in Thousand Oaks
Amgen was founded in Thousand Oaks, a nearby suburb of Los Angeles, more than 45 years ago. The company has made meaningful contributions to the local community in the form of employee volunteerism and philanthropic donations. It has also grown to become a global leader in the development, manufacture and delivery of biologic medicines to help fight some of the world’s toughest diseases. This latest expansion will bring innovation, highly skilled jobs, and a strong community presence to Thousand Oaks and Greater Los Angeles.
The groundbreaking event was attended by Thousand Oaks Mayor David Newman, Ventura County Supervisor Jeff Gorell and City Manager Drew Powers, along with other local policy and business leaders, as well as patient advocates who shared their appreciation for Amgen’s commitment to life-changing innovation.
“As a global leader in biotech, Amgen could locate anywhere on the planet, but it chose Thousand Oaks,” Mayor Newman said. “This is the kind of high-value, innovation-driven investment that defines our city’s economic future.”
“The $600 million expansion of the Amgen center for science and innovation is more than investing in jobs and economic growth,” said County Supervisor Jeff Gorell. “It represents a renewed commitment by Amgen to this community and a powerful step forward in their extraordinary life-saving mission.”
Building Towards the Future
The new center for science and innovation will integrate teams from both Research & Development and Process Development to foster a seamless transition from drug discovery to commercial manufacturing, accelerating the delivery of transformative therapies to patients.
“The vision for this building is very much the way we work here at Amgen, where chemists, biologists, physicians, patients, patient advocates and manufacturing operators all work together to reimagine solutions to some of the toughest diseases,” said Jay Bradner, executive vice president of R&D at Amgen, describing a space that bridges science and engineering in meaningful ways.
Esteban Santos, executive vice president of Operations at Amgen, added: “This investment in science and innovation furthers the promise of Amgen’s commitment to the Thousand Oaks community, as well as for the patients we serve around the world.”
The flexible, future-ready facility will incorporate advanced automation and digital capabilities, empowering researchers, scientists, and engineers to collaborate more efficiently and push the boundaries of science. It will also meet LEED Gold standards, reflecting Amgen’s dedication to sustainability and environmental stewardship.
Upon completion, the facility will be the most sustainable building on Amgen’s Thousand Oaks campus.